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Abstract. Various tumours, classically specified as 
either neuroendocrine or non-neuroendocrine, contain 
high numbers of somatostatin receptors, which enable 
in vivo localization of the primary tumour and its me- 
tastases by scintigraphy with the radiolabelled somato- 
statin analogue octreotide. In addition granulomas and 
autoimmune processes can be visualized because of lo- 
cal accumulation of somatostatin receptor-positive acti- 
vated mononuclear leucocytes. In many instances a 
positive scintigram predicts a favourable response to 
treatment with octreotide. It is tempting to speculate 
that octreotide labelled with an appropriate radionuclide 
might be used in cancer therapy. The successful appli- 
cation of radiolabelled octreotide in scintigraphy indi- 
cates the possible usefulness of other adiolabelled pep- 
tides, either native peptides or derivatives of these, in, 
for example, nuclear oncology. The small size of these 
peptides, e.g. bombesin and substance P, is of the utmost 
importance for a relatively fast blood clearance, thus 
leading to low background radioactivity. In this way 
peptides are powerful alternatives to (fragments of) 
monoclonal ntibodies, the application of which to scin- 
tigraphic localization of specific cell surface antigen- 
bearing tumours is plagued by slow blood clearance 
and, hence, high background levels. 
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Introduction 
Somatostatin and somatostatin receptors 
Somatostatin is a peptide hormone consisting of 14 
amino acids (SS-14). It is present in the hypothalamus, 
the cerebral cortex, the brain stem, the gastrointestinal 
tract and the pancreas. Somatostatin receptors have been 
identified on many cells of neuroendocrine origin, in- 
cluding the somatotroph cells of the anterior pituitary, 
the thyroid C cells and the pancreatic islet cells [1, 2]. 
Also cells not known as classically neuroendocrine, 
such as lymphocytes [3], may possess these receptors 
(Fig. 1). 
The information with regard to the interaction of so- 
matostatin analogues with the reported somatostatin re- 
ceptors is rather confusing. At the moment hree sub- 
types of human somatostatin receptors have been cloned 
[4, 5], while another type has been identified in rat pi- 
tuitary and brain [6, 7]. Somatostatin receptors are 
structurally related integral membrane glycoproteins. 
The human tissue distribution of cloned somatostatin 
receptors known so far is as follows: type I - stomach 
and jejunum; type II - brain, kidney and pancreatic is- 
lets; type III - pancreatic slets. On the basis of chemi- 
cal characteristics the rat somatostatin receptor (type 
IV) is probably different from these human subtypes. 
The somatostatin analogue octreotide inhibits somato- 
statin binding to receptor type II in the low nanomolar 
range, in contrast to much higher values for types I and 
III. Conflicting results have been described for the ef- 
fect of octreotide on somatostatin binding to type IV 
receptors, both sensitivity and non-sensitivity o octreo- 
tide having been reported [6, 7]. An explanation might 
be the existence of two type IV receptors with different 
affinities for octreotide. Among other things the re- 
ported differences in intracellular effector systems be- 
tween type II and type IV receptors point to the exist- 
ence of these two receptor subpopulations [8]. For in- 
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Fig. 1. Tumours and diseases with neuroendocrine c lls and/or 
activated leucocytes with increased ensity of somatostatin recep- 
tors, which can be visualized with [mIn-DTPA-D-Phet]-octreotide 
scintigraphy [11] 
stance, in contrast o type II (and type I), type IV (and 
type III) mediates its effects via inhibition of adenylyl 
cyclase activity. Since the effects of octreotide in human 
tissues seem to be related - at least in the pituitary and 
meningiomas - to inhibition of adenylyl cyclase activity 
[9], it is probable that a type IV-like somatostatin re- 
ceptor also exists in man, which, in addition to the type 
II receptor, can be visualized with [125I-Tyr3]-octreotide 
autoradiography and octreotide scintigraphy. 
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[10]. Other actions are (a) an antiproliferative effect on 
tumours, as has been found for instance in cultured 
breast cancer cell lines, in numerous animal tumour 
models and in neuroendocrine tumours in man and (b) 
specific regulation of immune responses (for a review, 
see [11]). The antiproliferative effect is ascribed to (a) 
inhibition of growth via induction of somatostatin re- 
ceptors, (b) inhibition of the release of hormones and 
growth factors such as growth hormone and insulin-like 
growth factor I (IGF-I), (c) inhibition of angiogenesis 
and (d) modulation of immunological activity. 
Distribution of somatostatin receptors 
in disease states 
Besides in normal tissue, somatostatin receptors have 
been demonstrated in most neuroendocrine tumours, 
many of which are derived from cells belonging to the 
amine precursor uptake and decarboxylation (APUD) 
system [12, 13]. These neuroendocrine tumours contain 
secretory granules [14]. Recently, somatostatin recep- 
tors have also been identified in tumours of the central 
nervous system (CNS) [15, 16], breast [17], lung [18] 
and lymphoid tissue [19, 20]. Tables 1-3 show the in- 
cidence of somatostatin receptors in various tumours 
and diseases. 
The affinity of somatostatin for its receptor on tu- 
mours and lymphomas is in the low nanomolar ange. 
In general, neuroendocrine tumours, lymphomas and ac- 
tivated leucocytes have an increased density of soma- 
tostatin receptors, which enables their visualization with 
radiolabelled somatostatin (analogues). 
Somatostatin effects in vitro and in vivo 
In the central nervous system somatostatin acts as a neu- 
rotransmitter, whereas its hormonal activities include 
the inhibition of the release (physiological and tumor- 
ous) of growth hormone, insulin, glucagon and gastrin 
[1231 Tyr3] oc t reot ide  and  
[1111n DTPA D Phe~] oc t reot ide  
In 1987 we introduced the somatostatin analogue [Tyr3] - 
octreotide labelled with iodine-123 for the localization 
of primary and metastatic somatostatin receptor-rich tu- 
Table 1. Incidence of somatostatin recep- 
tors in neuroendocrine tumours: results 
of [mIn-DTPA-D-Phe~]-octreotide scintig- 
raphy, as compared to in vitro somatosta- 
tin receptor autoradiography. In vivo and 
in vitro data are from different patient 
groups 
In vivo scintigraphy In vitro receptor status 
GH-producing pituitary tumour 7/10 70% 45/46 98% 
TSH-producing pituitary turnout 2/2 100% - - 
Non-functioning pituitary tumour 12/16 75% 12/22 55% 
Gastrinoma 12/12 100% 6/6 100% 
Insulinoma 14/23 61% 8/I 1 72% 
Glucagonoma 3/3 100% 2/2 100% 
Unclassified APUDoma 16/18 89 % 4/4 100% 
Paraganglioma 33/33 100% 11/12 92% 
Medullary thyroid carcinoma 20/28 71% 10/26 38% 
Neuroblastoma 8/9 89% 15/23 65% 
Phaeochromocytoma 12/14 86% 38/52 73% 
Carcinoid 69/72 96% 54/62 88% 
Small cell lung cancer 34/34 100% 4/7 57% 
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Table 2. Incidence of somatostatin receptors in non-neuroendo- 
crine tumours: results of [mIn-DTPA-t~-Phe~]-octreotide scintig- 
raphy as compared to in vitro somatostatin receptor autoradiogra- 
phy. In vivo and in vitro data are from different patient groups 
In vivo In vitro 
scintigraphy receptor status 
Non-small cell lung cancer 36/36 100% 0/17 0% 
Meningiomas 14/14 100% 54/55 98% 
Breast cancer 37/50 74% 33/72 46% 
Exocrine pancreatic tumours 0/24 0% 0/12 0% 
Astrocytoma 4/6 67% 14/17 82% 
Table 3. Incidence of somatostatin receptors in granulomatous 
and autoimmune diseases: results of [mIn-DTPA-D-Phe~]-octreo - 
tide scintigraphy as compared to in vitro somatostatin receptor 
autoradiography. In vivo and in vitro data are from different pa- 
tient groups. 
In vivo In vitro 
scintigraphy receptor status 
Non-Hodgkin's lymphoma 59/74 80% 26/30 87% 
Hodgkin's disease 23/24 96% 2/2 100% 
Sarcoidosis 23/23 100% 3/3 100% 
Wegener's granulomatosis 4/4 100% - 
Tuberculosis 6/6 100% 2/2 100% 
Graves' disease: thyroid 9 a 1 
Graves' ophthalmopathy 25 b 
Increased accumulation f radioactivity in the thyroid gland in 
untreated hyperthyroidism 
b Correlation with clinical activity score of orbital inflammation 
mours, such as neuroendocrine tumours [21-27]. Our 
experience in more than 100 patients points to several 
drawbacks of [123I-Tyr3]-octreotide for in vivo scinti- 
graphy [28]. First, the labelling of [Tyr3]-octreotide with 
~23I is cumbersome and requires pecial skills which are 
only available in the larger departments of nuclear 
medicine. Second, Na~23I of high specific activity is ex- 
pensive and is hardly available worldwide. Third, the 
timing of the labelling and scanning procedures i  de- 
pendent on the logistics of the production and delivery 
of Na123I. Finally, substantial accumulation of radioac- 
tivity is seen in the intestines, since a major part o f  
[123I-Tyr3]-octreotide is rapidly cleared via the liver and 
biliary system. This makes the interpretation of planar 
and single-photon emission tomographic (SPET) images 
of the upper abdomen difficult. Some of these problems 
can be solved by replacing 123I with indium-i l l ,  which 
also improves cintigraphy 24-48 h after application by 
virtue of its longer half-life [29]. Binding of rain to the 
somatostatin analogue octreotide has been carried out 
by complexing with a diethylene triamine penta-acetic 
acid (DTPA) group coupled to the aNH2 group of the 
N-terminal D-Phe residue [30]. In rats, it appeared that 
[mIn-DTPA-D-Phel]-octreotide (a) is excreted via the 
kidneys, (b) shows only minor accumulation i the liver 
and (c) has an initial plasma half-life in the order of 
minutes [311. 
[1111n-DTPA-D-Phel]-octreotide 
as a somatostatin analogue 
In vitro receptor binding studies using [123I-Tyr3]-octreo- 
tide and [mIn-DTPA-D-Phel]-octreotide show affinities 
for the rat brain cortex in the low nanomolar ange, 
with the highest affinity for the first radioligand [301. 
The molecular weights of SS-14 and its chelated ana- 
logue [DTPA-D-Phel]-octreotide are 1.6 and 1.4 kDa, 
respectively. Thus the maximal peak blood level after 
intravenous injection of 10 gg [DTPA-D-Phel]-octreo - 
tide in man is 0.5 nM, assuming an instant passage into 
the interstitium and a complete distribution in an extra- 
cellular volume of 14 1. The simultaneous renal clear- 
ance of this analogue might prevent [DTPA-D-Phel]-oc - 
treotide from reaching a concentration atthe membrane 
receptor which equals the receptor affinity. Pretreatment 
of rats bearing implanted somatostatin receptor-positive 
tumours with a high dose of unlabelled octreotide 
blocks the binding of injected radiolabelled octreotide, 
pointing to in vivo saturation of the receptor [31]. 
Metabolism in man 
The metabolic properties of [mIn-DTPA-D-Phel]-octreo - 
tide turned out to be similar in rat and man. After in- 
travenous administration, [ll~In-DTPA-D-Phel]-octreo - 
tide is rapidly cleared from the circulation via the kid- 
neys. However, the initial disappearance from the cir- 
culation is considerably slower than that of [123I-Tyr3]- 
octreotide [29]. This slower initial clearance, combined 
with the longer physical half-life of lllIn (tl/2 = 2.8 days 
for H~In vs 13.2 h for 123I) results in a longer residence 
time of the radiopharmaceutical in the tissues. The pres- 
ence of a lower total body radioactivity 24 h after in- 
jection of [ltlIn-DTPA-D-Phel]-octreotide l ads to a 
lower background radioactivity [29]. The higher back- 
ground radioactivity with [123I-Tyr3]-octreotide is due to 
much higher circulating levels of degradation products 
than is the case with [mIn-DTPA-D-Phel]-octreotide. 
Therefore, [mIn-DTPA-D-Phe~]-octreotide is a more 
suitable radioligand to localize somatostatin receptor- 
rich tissues. Furthermore, using [n~In-DTPA-D-Phel]- 
octreotide, interpretation of scintigrams of the abdomi- 
nal region is less affected by intestinal background ra- 
dioactivity. This contrasts remarkably with [123I-Tyr3]- 
octreotide, because the hepato-biliary clearance of this 
compound results in a higher hepatic and intestinal ac- 
cumulation of radioactivity, which scarcely can be over- 
come with laxatives (1.9%--~2.2% dose/liver/4---~24 h 
for [111In-DTPA-D-Phel]-octreotide v rsus 28%-->6% 
dose/liver/4---~24 h for [123I-Tyr3]-octreotide, respec- 
tively) [28, 29]. 
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Fig. 2. Blood clearance in man of l0 ~tg [mIn-DTPA-D-PhcI]-oc - 
treotide (,) [29] and 1-10 mg F(ab)2 (A) and Fab (B) of anti- 
CEA monoclonal ntibodies [65] 
Analysis of the chemical status of plasma radioac- 
tivity during the first 4 h after injection shows mainly 
peptide-bound lllIn in the form of the original [Illln- 
DTPA-D-Phel]-octreotide. Similarly, analysis of radio- 
activity in the urine shows predominantly intact [mIn- 
DTPA-D-Phe~]-octreotide during the first hours after in- 
jection. Furthermore, peptide-bound radioactivity in 
plasma and urine still possesses somatostatin receptor- 
binding properties as demonstrated by specific binding 
to rat brain cortex membranes. Degradation of [111In- 
DTPA-D-Phel]-octreotide was observed only in plasma 
and urine samples obtained more than 4 h after intra- 
venous injection of the radiopharmaceutical, when cir- 
culating radioactivity amounted to less than 10% of the 
administered ose (Fig. 2) [291. The rapid appearance 
of intact [~HIn-DTPA-D-Phe~]-octreotide n the urine in- 
dicates an effective renal clearance of this radiopharma- 
ceutical. The different metabolism of [mIn-DTPA-D- 
Phe~]-octreotide compared with [~23I-Tyr3]-octreotide in- 
dicates that the modification of octreotide with the mIn- 
DTPA group inhibits hepatic clearance and/or facilitates 
renal clearance. Rat liver perfusion studies have indeed 
shown that [mln-DTPA-D-Phel]-octreotide is cleared 
much more slowly by the liver than [123I-Tyr3]-octreo- 
tide (unpublished). The relatively long residence time 
of [mIn-DTPA-D-Phel]-octreotide in the kidneys sug- 
gests that following glomerular filtration part of the la- 
bel is actively reabsorbed in the tubules [31]. 
Dos imetry  
Since scintigraphy with [i23I-Tyr3]-octreotide has the 
drawbacks mentioned previously, while [Tyr3]-octreo - 
tide is not commercially available, the following part 
of this review will be focused on [111In-DTPA-D-Phe~]- 
octreotide scintigraphy. The recommended oses are 
111 and 222 MBq [IJlIn-DTPA-D-Phel]-octreotide for 
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planar scintigraphy and SPET, respectively, with a high 
specific activity. 
The effective dose equivalent of 111-222 MBq 
[lllIn-DTPA-D-Phel]-octreotide (8-16 mSv), although 
somewhat higher than that of [123I-Tyr3]-octreotide (8- 
12 mSv/370-555 MBq) [28, 29], is comparable to val- 
ues for other lllIn-labelled radiopharmaceuticals [32] 
and is acceptable in view of the clinical indications. 
Furthermore these radiation doses have to be compared 
with the values of commonly used imaging techniques 
for these clinical indications, e.g. CT (chest: 7-1l mSv) 
and angiography (5-25 mSv). 
Imag ing  protoco l  
fo r  [1111n-DTPA-D-Phel ] -octreot ide sc in t ig raphy  
Planar and SPET images are obtained with a large field 
of view gamma camera, equipped with a medium-en- 
ergy parallel-hole collimator. The pulse height analyser 
windows are centered over both rain photon peaks (172 
keV and 245 keV) with a window width of 20%. Data 
from both windows are added to the acquisition frames. 
For planar images the acquisition parameters are as fol- 
lows: (a) 128x128 word matrix, (b) images of 
head/neck: 300000 preset counts (or max. 15 min) at 
24 h and 15 min preset ime (=200000 counts) at 48 h 
after injection, (c) images of the remainder of the body, 
with separate images of the chest (including as little as 
possible of the liver and spleen) and the upper (includ- 
ing liver/spleen and kidneys) and lower abdomen: 500 
000 counts (or max. 15 min). For SPET with a single- 
head camera the aqcuisition parameters are: (a) 60 pro- 
jections, (b) 64x64 word matrix and (c) 45-60 s acqui- 
sition time per projection, while for SPET with a three- 
head camera the corresponding parameters are (a) 120 
projections, (b) 64x64 word matrix, and (c) 30 s acqui- 
sition time per step (45 s for SPET of the head). If a 
short counting time is required to obtain these numbers 
of counts, which especially tends to be the case when 
tissues with relatively high accumulation (e.g. abdomi- 
nal organs) are included in the field of view, additional 
images with a longer counting time are recommended 
in order to visualize also lesions with low somatostatin 
receptor density. SPET analysis is performed with a 
Wiener filter on original data. The filtered data are re- 
constructed with a Ramp filter. 
Planar and SPET studies are preferably performed 
24 h after injection of the radiopharmaceutical. Planar 
studies after both 24 and 48 h can be carried out with 
the same protocol. Repeat scintigraphy after 48 h is es- 
pecially indicated when 24-h scintigraphy shows accu- 
mulation in the abdomen, which can represent radioac- 
tive bowel content. Four-hour images of the abdomen 
are recommended by others since radioactive bowel 
content is almost always absent. One should realize, 
however, that the relatively high background radioac- 
tivity at 4 h might obscure the localization of lesions 
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with low receptor density. These lesions may be visible 
at 24 h because of a 6 times lower background radio- 
activity at 24 h after injection of the radioligand and a 
relatively long effective half-life n the tumour. This dif- 
ference in results of 4- and 24-h images necessitates 
scanning after 48 h, since the interpretation f the dif- 
ference in abdominal accumulation is twofold: radioac- 
tive bowel content or the accumulation i  a lesion with 
low receptor density. If the abdomen is the region of 
interest he use of laxatives is highly recommended 
starting from the moment of injection. 
Normal tissue accumulation 
Accumulation of radioactivity after intravenous admini- 
stration of [mln-DTPA-D-Phe~]-octreotide n man is ob- 
served in the pituitary (see "Arguments that [mln- 
DTPA-D-Phel]-octreotide scintigraphy is receptor imag- 
ing") and thyroid gland, the spleen, the liver (low he- 
patobiliary clearance), the kidneys and the urinary blad- 
der. The gallbladder is occasionally seen on the planar 
images and often on the 24-h SPET images, while the 
presence of intestinal radioactivity (mainly in the colon 
at 24 h) depends on the simultaneous e of laxatives. 
The relatively low clearance of the radioligand via the 
hepato-biliary system favours its use in SPET of the 
abdomen, which is strongly indicated for the localiza- 
tion of small pancreatic endocrine tumours. For in- 
stance, overprojection of kidney radioactivity can ob- 
scure lesions in the head and tail of the pancreas. The 
same is true for lesions in the stomach, which can be 
missed by overprojection f radioactivity of the left kid- 
ney and spleen. Furthermore hepatic receptor-positive 
turnouts can be better localized with SPET. 
At present, it s unclear what mechanism is respon- 
sible for the imaging of the thyroid (see "autoimmune 
diseases"). Binding studies with murine spleen cells and 
autoradiography of normal spleen tissue revealed the 
presence of somatostatin receptors [33; J.C. Reubi et al. 
unpublished]; however, the exact cell type (or types) 
bearing the somatostatin receptor has not yet been iden- 
tified in man. Patients on octreotide treatment show a 
diminished (50%-100%, depending on the octreotide 
dose) accumulation of radioligand in the spleen, com- 
patible with occupancy of spleen somatostatin receptors 
by the unlabelled octreotide. The accumulation i the 
urinary tract is explained by the metabolism (see above) 
of [lllIn-DTPA-v-Phe~]-octreotide. 
For a correct interpretation of [mIn-DTPA-D-Phel]- 
octreotide scintigrams one must bear in mind the fol- 
lowing: 
1. During the typical season of epidemic common 
cold/influenza transient accumulation i the nasal re- 
gion and lung hili has been observed. It is at present 
unknown whether this phenomenon is based on binding 
to increased numbers of activated lymphocytes in the 
respiratory tract, as has been described for human gut 
lymphoid tissue [20]. 
2. External irradiation of the lung can cause local 
pulmonary accumulation f [mln-DTPA-D-Phel]-octreo - 
tide. 
3. Bleomycin can likewise cause such local pulmo- 
nary accumulation. 




Using autoradiography in most cases (see above), so- 
matostatin receptors have been demonstrated in a vari- 
ety of (neuroendocrine) tumours and in diseases with 
activated leucocytes. In virtually all cases the density 
of these receptors was high enough to allow in vivo 
visualization of these processes as well (Fig. 1 and Ta- 
bles 1-3). Figure 3 illustrates the normal scintigraphic 
distribution of [111In-DTPA-D-Phel]-octreotide radiolig- 
and in man. 
Since 1989 1050 patients have undergone [111In- 
DTPA-o-Phel]-octreotide scintigraphy in our institution, 
of whom 735 have complete records, implying at least 
an unequivocal diagnosis and optimal anatomical infor- 
mation, whether provided by the usual imaging modali- 
ties, by histology and/or by autopsy. The data in the 
following are derived from the patients with complete 
records. In none of the patients has any side-effect been 
Fig. 3. Normal scintigraphic distribution f [mln-DTPA-D-PheL]- 
octreotide in man 24 h after i.v. injection. Usually the pituitary, 
thyroid gland, liver, spleen, kidneys and urinary bladder arevisu- 
alized. Visualization of intestinal radioactivity depends on time 
of scintigraphy (see text) and use of laxatives. Views: top left, 
left lateral part of the head; top right, anterior chest; lower left, 
anterior abdomen, lower right, posterior abdomen 
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noticed. To avoid paradoxical hypoglycaemia, the only 
precaution taken was a glucose infusion in the case of 
an insulinoma if the response to octreotide was un- 
known beforehand. 
"Neuroendocrine " tumours 
Pituitary tumours. Somatostatin receptors have been 
demonstrated in vitro on virtually all growth hormone 
(GH)-producing pituitary adenomas that have been in- 
vestigated [34]. Also, in vivo somatostatin receptor im- 
aging has been positive in most cases (see Table 1). A 
close correlation between the presence of somatostatin 
receptors on GH-producing pituitary tumours in vitro 
and the preoperative in vivo sensitivity of tumourous 
GH secretion to octreotide has been reported [34]. Like- 
wise, the scan positivity or negativity during in vivo 
octreotide scintigraphy is linked to the sensitivity of GH 
release to suppression by octreotide [35, 36]. 
In cooperation with others we extensively studied a 
group of seven patients with clinically non-functioning 
pituitary adenomas. In six of the seven patients the ade- 
nomas were somatostatin receptor positive both in vivo 
and in vitro [37]. Long-term, high-dose octreotide treat- 
ment in four of these patients resulted in some reduction 
of tumourous gonadotropin secretion i  two patients and 
improvement of visual field defects in three, but sub- 
stantial tumour size reduction was not obseverd in any 
of the patients. 
Not only GH-producing or clinically nonfunctioning 
pituitary adenomas but also TSH-secreting pituitary tu- 
mours can be visualized using octreotide scintigraphy 
(Table 2). In addition, other intra- or parasellar tumours, 
like pituitary metastases from somatostatin receptor- 
positive neoplasms, e.g. breast cancer or parasellar men- 
ingiomas and lymphomas, may be positive. Therefore, 
in our opinion, the differential diagnostic value of oc- 
treotide scintigraphy in pituitary tumours is limited. 
Endocrine pancreatic turnouts. The majority of peptide 
hormone-producing endocrine tumours originate from 
the islet cells of the pancreas, but they may also occur 
in the stomach, duodenum or intestines. These tumours 
are named after the hormones they secrete, e.g. astri- 
nomas, insulinomas, glucagonomas. Octreotide has 
been shown to be of special benefit in the treatment of 
the clinical syndromes caused by hypersecretion of
these hormones [38, 39]. Though surgery is the treat- 
ment of choice in most patients, localization of the pri- 
mary tumour as well as metastatic tumours may prove 
very difficult or even impossible with conventional im- 
aging methods [40]. As is clear from Table 3, the ma- 
jority of the endocrine pancreatic tumours can be visu- 
alized using [mln-DTPA-D-Phel]-octreotide scintigra- 
phy. Therefore, octreotide scintigraphy can be of great 
value in localizing tumour sites in such patients, includ- 
ing in those cases where surgery is indicated but local- 
ization of the tumour is not possible with conventional 
imaging modalities. 
Special mention should be made of the failure to 
visualize some insulinomas with [1HIn-DTPA-D-Phe~] - 
octreotide scintigraphy. We previously described a pa- 
tient whose insulinoma was not localized during [123I- 
Tyr3]-octreotide scintigraphy and in whom insulin levels 
did not respond to octreotide administration. Using in 
vitro techniques, however, high-affinity binding sites 
were demonstrated for SS-14 and SS-28, but not for 
octreotide. Also, SS-14 and SS-28, but not octreotide, 
suppressed insulin release from cultured cells in vitro 
[23]. This points to the existence of somatostatin recep- 
tor subclasses on this type of tumour. It should be em- 
phasized, however, that on by far the majority of soma- 
tostatin receptor-positive tumours the receptors bind 
both native somatostatin a d octreotide (analogues). 
In contrast o endocrine pancreatic tumours, all hu- 
man exocrine adenocarcinomas of the pancreas that we 
have so far investigated have been negative, both in 
vivo and in vitro (Table 2). Although occasionally a pre- 
sumed exocrine pancreatic tumour was visualized ur- 
ing octreotide scintigraphy, careful re-examination of
the tumour tissue, appropriate immunostaining and elec- 
tron microscopy revealed the neuroendocrine origin of 
these tumours, thus leading to a revision of the original 
diagnosis. 
Paragangliomas. Using [1~lln-DTPA-D-Phel]-octreotide 
scintigraphy, 50 of 53 (94%) known localizations in 25 
well-documented patients with paragangliomas were 
visualized [41]. In two patients, three localizations were 
missed during octreotide scintigraphy. Unexpected ad- 
ditional paraganglioma sites, not detected or not inves- 
tigated with conventional imaging techniques, were 
found in 9 out of 25 patients (36%) with known para- 
gangliomas. Only in four of these were the supposed 
tumour localizations ubsequently also demonstrated 
with other imaging modalities. 
High-resolution computed tomography (CT) scan- 
ning in combination with magnetic resonance imaging 
(MRI), with and without gadolinium-DTPA enhance- 
ment, is an effective imaging regimen for paragan- 
gliomas [42]. However, this type of imaging is usually 
limited to the site where a paraganglioma is clinically 
suspected. In our series, CT scanning or MRI of the 
site where a paraganglioma w s primarily expected was 
in most cases combined with ultrasound of the neck, in 
order to detect multicentricity. With [Hlln-DTPA-D- 
Phel]-octreotide total-body scintigraphy, however, unex- 
pected additional paraganglioma sites, not detected or 
not investigated with conventional imaging techniques, 
were found in one-third of the patients with known 
paragangliomas. This finding is of special interest since 
multicentricity and distant metastases ach may occur 
in 10% of cases [43]. In this respect, one of the major 
advantages of octreotide scintigraphy is that it provides 
information on potential tumour sites in the whole body. 
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It could thus be used as a screening test, to be followed 
by CT scanning, MRI, or ultrasound of the sites at 
which abnormalities are found. 
Neuroblastomas nd phaeochromocytomas. In eight out 
of nine patients with neuroblastoma [nlIn-DTPA-o- 
Phel]-octreotide scintigraphy visualized the tumour de- 
posits. Patients with somatostatin receptor-positive n u- 
roblastomas eem to have a longer survival (L. Kvols, 
personal communication) compared with the receptor- 
negative ones. 
Of 14 phaeochromocytomas, 12 were somatostatin 
receptor-positive in vivo. A drawback of the use of 
[lnIn-DTPA-D-Phel]-octreotide for localization of this 
tumour in the adrenal gland is the relatively high radio- 
ligand accumulation in the kidneys. Metaiodobenzyl- 
guanidine (MIBG) scintigraphy is preferred for its lo- 
calization in this region. Discrepancies between whole- 
body scintigraphy with [mIn-DTPA-D-Phe~]-octreotide 
and MIBG in the staging of phaeochromocytomas h ve 
been observed (see comparison with MIBG). The im- 
portance of this complementary adioligand accumula- 
tion, both diagnostic and therapeutic, will have to be 
investigated in future studies. 
Medullary thyroid carcinoma. In 11 of 17 well-docu- 
mented patients with medullary thyroid carcinoma 
(MTC) (65%), tumour localizations were demonstrated 
using [mIn-DTPA-D-Phel]-octreotide scintigraphy [44]. 
However, seven patients with turnout localizations in 
the liver and one patient with the primary tumour still 
present in the thyroid showed a homogeneous distribu- 
tion of radioactivity in these organs during [mln-DTPA- 
~-Phe~]-octreotide scintigraphy. Thus, the amount of ra- 
dioactivity in these tumours was visually undistinguish- 
able from that in the surrounding organ tissue. It ap- 
peared that subtraction techniques with radiolabelled 
colloid and radioiodine, respectively, are of help in 
demonstrating the binding of [lllln-DTPA-D-Phe~]-oc - 
treotide to these tumours, especially when [111In-DTPA- 
D-Phel]-octreotide scintigraphy shows a homogeneous 
distribution of radioactivity in these organs. Somatosta- 
tin receptors were demonstrated in vitro on all five in- 
vestigated tumours which had also been visualized in 
vivo, as well as on one tumour that had not. The ratio 
of serum calcitonin (CT) to carcino-embryonic antigen 
(CEA) concentrations was significantly higher in pa- 
tients whose MTCs were visualized during octreotide 
scintigraphy than in those whose tumours were not. 
From this study, we concluded that: (a) in the ma- 
jority of patients with metastatic MTC, tumour sites can 
be visualized using octreotide scintigraphy, although 
this technique is insensitive in detecting liver metastases 
or intrathyroidal tumour when no subtraction techniques 
are applied; (b) the visualization of MTC during in vivo 
somatostatin receptor imaging correlates with the in vi- 
tro presence of somatostatin receptors; (c) higher serum 
CT to CEA ratios in patients whose MTCs are visual- 
Fig. 4a-f. Octreotide scintigraphy in a patient with carcinoid syn- 
drome, 24 h after injection of [mIn-DTPA-D-Phe~]-octreotide. a 
Right lateral image of the head and neck, with abnormal accu- 
mulation of radioactivity along the right neck, i  the mediastinum 
and in the l ft supraclavicular region, b, e Anterior (b) and pos- 
terior (e) images of the thorax. Note the many sites of abnormal 
accumulation of labelled octreotide, many of which represent 
bone metastases, d Anterior abdominal image, on which an ir- 
regular liver uptake can be seen, with many sites of abnormal 
accumulation f labelled octreotide, e Posterior abdominal image, 
showing prominent hot spots in the liver, spine and sacroileal 
joints, f Anterior lower abdominal image: Apart from normal ac- 
cumulation of radioactivity in the bladder (medial spot in the im- 
age), many sites of abnormal accumulation of radioactivity are 
seen. Of special interest are the hot spots on the lower left and 
right, representing metastases in the femurs 
ized during octreotide scintigraphy might imply that so- 
matostatin receptors are present on the more differenti- 
ated forms of MTC. 
Carcinoids Scintigraphy with [123I-Tyr3]-octreotide and 
[nlln-DTPA-D-Phel]-octreotide was performed in 52 pa- 
tients diagnosed as, suspected of, or at risk of having 
carcinoid tumours [45]. In 32 of 37 (86%) patients in 
whom histologically proven carcinoids were still pre- 
sent, known tumour sites were visualized. Using [123I- 
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Tyr3]-octreotide, 24 of 40 (60%) known extrahepatic 
sites were visualized, whereas all 12 (100%) extrahe- 
patic lesions were visualized after injection of [mIn- 
DTPA-D-Phe~]-octreotide. An example in a patient not 
included in the cited study is given in Fig. 4. Known 
liver metastases were not visualized with octreotide 
scintigraphy in 12 of 24 patients. In all but two of these, 
a homogeneous distribution of radioactivity was ob- 
served in the liver. This was probably because these 
liver metastases accumulated about as much radioactiv- 
ity as does normal liver tissue. 
Previously unsuspected extrahepatic localizations or 
sites not recognized with other imaging techniques were 
found in 20 of the 37 patients. In 3 of 11 patients who 
were thought o have been surgically cured and in four 
of four patients who were suspected of having carci- 
noids, octreotide scintigraphy showed abnormal accu- 
mulation of radioactivity. Histological or radiological 
evidence that additional sites noticed on octreotide scin- 
tigrams indeed represented tumour tissue has so far 
been obtained in ten patients. Visualization of extrahe- 
patic carcinoid localizations did not depend on the site 
of the tumour or on the presence or absence of hormo- 
nal hypersecretion, as measured by urinary 5-hydroxy- 
indoleacetic acid (5-HIAA) and serum o~-subunit con- 
centrations. 
Apart from its use for tumour localization, octreotide 
scintigraphy, as a consequence of its ability to demon- 
strate somatostatin receptor-positive tumours, could be 
used to select those patients with the carcinoid syn- 
drome who are likely to respond favourably to octreo- 
tide treatment. 
Comparison with results of other 
investigators 
Using [~23I-Tyr3]-octreotide scintigraphy, Faglia et al. 
[35] reported positive scans in three out of three patients 
with pituitary acromegaly and in two out of eight pa- 
tients with clinically non-functioning pituitary tumours, 
but in none of three patients with prolactinomas. Ur et 
al. [36] found positive scans in 12 out of 15 patients 
with pituitary acromegaly and Becker et al. [46] de- 
scribed positive scans in 23 out of 35 patients with a 
variety of tumours, the majority of which were of 
neuroendocrine origin. 
Using H~In-octreotide scintigraphy, Bomjani et al. 
[47] found four out of five carcinoids, two out of three 
insulinomas and two out of two pituitary tumours to be 
somatostatin receptor positive in vivo. Also, Pauwels et 
al. [48] described the localization of 23 out of 26 gas- 
tro-entero-pancreatic (GEP) tumours and Van Dongen 
et al. [49] reported positive scans in four of four patients 
with carcinoids, one of one with MTC and one of one 
with an unclassified APUDoma using this technique. Iv- 
ancevic et al. [50] reported a sensitivity of 67%-83% 
in GEP tumours and carcinoids, while Joseph et al. [51], 
in a study of 38 patients, reported positive scans in 10 
of 11 patients with gastrinomas, 10 of 11 patients with 
carcinoids, one of two patients with insulinomas and 10 
of 14 patients with unclassified neuroendocrine tu- 
mours. The last two authors both mention the localiza- 
tion of tumour sites undetected with other imaging tech- 
niques. 
Summarizing, it has been confirmed by various 
groups of investigators that most neuroendocrine tu- 




in neuroendocrine tumours 
S. Pauwels and co-workers [UCL, Brussels, Belgium, 
unpublished] have calculated the accumulation of [mln- 
DTPA-D-Phel]-octreotide in 47 GEP tumours in 22 pa- 
tients. The mean value appeared to be 0.0123% dose 
per gram tumour tissue. The respective maximal and 
minimal values were 0.0527% and 0.0016% dose per 
gram tumour tissue. Our experience, although based on 
a lower number of selected patients, points to an accu- 
mulation of 0.0067% to 0.2% dose per gram tumour 
tissue (GEP tumours and paragangliomas). Tumour up- 
take percentages measured between 4 h and 168 h after 
injection of [mln-DTPA-D-Phe~]-octreotide decrease by 
about 25%. Given a blood-pool radioactivity at 4 h of 
0.002% dose per ml blood [29] it seems, taking into 
account the measured minimum tumour value of 
0.0016% dose per gram, that the tumour-to-background 
ratio, especially in endocrine tumours which are highly 
vascularized, might be about 1:1 at 4 h. Therefore these 
tumours with an apparently low receptor density can 
then be missed with [mIn-DTPA-D-Phe~]-octreotide 
scintigraphy. Since the blood-pool radioactivity de- 
creases ixfold from 4 h to 24 h after injection of [111In- 
DTPA-D-Phel]-octreotide [29] the optimal time-point to 
localize these tumours is 24 h or later. 
Possible factors interfering with the 
visualization of neuroendocrine tumours with 
[1111n-DTPA-o-Phe~]-octreotide 
Events and factors in the direct vicinity of the somato- 
statin membrane receptors can affect the results of the 
visualization of some processes with radiolabelled oc- 
treotide. These include the presence of unlabelled so- 
matostatin e.g. by auto-, para- or endocrine production 
of somatostatin (eg. in phaeochromocytoma and medul- 
lary thyroid carcinoma) or after administration of a so- 
matostatin (analogue) (e.g. in carcinoids). This may re- 
sult in low or absent accumulation of the radioligand, 
because of occupancy of, competition with or down- 
regulation of the receptors by the unlabelled ligand. 
The presence of different subtypes of somatostatin 
receptors with a different affinity for the radioligand 
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may also determine the result of the scintigram (e.g. in 
insulinomas and medullary thyroid carcinomas). 
Lastly, variable differentiation grade of the primary 
tumour and its metastases and, therefore, variable ex- 
pression of the somatostatin receptors have been ob- 
served in medullary thyroid carcinomas [52]. 
Results of somatostatin receptor imaging 
in various tumours and diseases 
Brain tumours 
All meningiomas have high numbers of somatostatin re- 
ceptors and [mIn-DTPA-D-Phel]-octreotide scintigraphy 
localized this tumour in all 14 investigated patients. 
Meningiomas are tumours which arise outside the 
blood-brain barrier. This presumably allows them to be 
visualized so clearly. The high somatostatin receptor 
content of the normal brain cannot be visualized by 
scintigraphy because the normal blood-brain barrier is 
not penetrated by somatostatin a d octreotide. 
The majority of well-differentiated astrocytomas 
(grade I and II) are somatostatin receptor positive; in 
the undifferentiated glioblastomas (grade IV) somato- 
statin receptors are absent. An inverse relationship be- 
tween the presence of somatostatin and epidermal 
growth factor (EGF) receptors has been observed. In 
grade III astrocytomas both types of receptor can be 
found [53]. Four out of six astrocytomas were visual- 
ized with radiolabelled octreotide scintigraphy. A pre- 
requisite for the localization with this radioligand is a 
locally open blood-brain barrier. Especially in the lower 
grade astrocytomas this barrier might be unperturbed. 
It is tempting to speculate that, if somatostatin a d EGF 
derivatives capable of passing the intact blood-brain 
barrier were to be developed, scintigraphy with a "cock- 
tail" of such derivatives could form a new approach that 
would enable the grading of glia-derived brain tumours 
in vivo (for a review, see [54]). 
Merkel cell tumours 
Merkel cells are distributed throughout the normal skin 
and express anumber of neuroendocrine characteristics. 
Trabecular carcinomas of the skin (Merkel cell tumours, 
cutaneous APUDomas, neuroendocrine carcinomas of 
the skin) are aggressive tumours of the skin with a high 
incidence of spread to regional ymph nodes (45%- 
91%) and distant metastases (18%-52%). In four out of 
the five patients tudied with octreotide scintigraphy in
whom tumour had also been detected by CT and/or ul- 
trasound, these sites were recognized on the scinti- 
grams. In one patient, a tumour with a diameter of less 
than 0.5 cm was missed with all these techniques. In 
two of these five patients octreotide scintigraphy dem- 
onstrated more metastatic tumour localizations than had 
previously been recognized [26]. 
Lung tumours 
[111In-DTPA-D-Phe~]-octreotide scintigraphy revealed 
the primary tumours and their metastases (e.g. in the 
brain) in all 34 patients with small cell lung cancer 
(SCLC), whereas only the primary tumours were visu- 
alized in all 36 patients with non-SCLCs. As somato- 
statin receptors are absent on most non-SCLCs investi- 
gated thus far, their in vivo visualization is probably 
due to uptake of radioactivity by the tissue surrounding 
the tumour. In theory one could consider the possibility 
of an accumulation of somatostatin receptor-positive 
immune cells and/or neuroendocrine c lls in the imme- 
diate vicinity of the tumour. This is presently being in- 
vestigated. 
Breast cancer 
In 74% of patients with stage I or II breast cancer the 
primary turnouts can be visualized. Stages I and II 
(<2 cm and 2-5 cm, respectively) are nowadays the 
most common stages as a result of the introduction of 
population screening programmes. Axillary lymph node 
metastases have been visualized in four of 13 patients 
with impalpable axillary lymph nodes [C. van Eijck et 
al., unpublished]. The role of [1~1In-DTPA-D-Phel]-oc - 
treotide scintigraphy in imaging breast cancer is at pre- 
sent unknown. It seems that in operated patients with 
somatostatin receptor-positive breast cancer, octreotide 
scintigraphy might be of use for the early detection of 
symptom-free r currences [C. van Eijck et al., unpub- 
lished]. Furthermore, it has been reported from a retro- 
spective study that 82% of patients with somatostatin 
receptor-positive tumours have a 5-year disease-free 
survival compared with 46% of patients with somato- 
statin receptor-negative br ast cancer [55]. 
Other tumours and diseases 
In addition to the neuroendocrine c lls, APUD-cell de- 
rived tumours and breast cancer, somatostatin receptors 
have also been characterized ona variety of white blood 
cells [3, 33, 56] and human leukaemic ells in lym- 
phoblastic leukaemia nd non-lymphocytic leukaemia. 
Below, the results of in vivo somatostatin receptor im- 
aging in some of these diseases are summarized. 
Malignant lymphomas. In the first ten patients with 
Hodgkin's disease or non-Hodgkin's lymphoma who 
were investigated in our hospital, the lymphoma depos- 
its were visualized with [~lqn-DTPA-D-Phel]-octreotide 
scintigraphy [57]. In four patients, previously unrecog- 
nized additional tumour localizations were found. In 
four cases tissue biopsies were taken and confirmed by 
autoradiography to be somatostatin receptor positive. 
Using in vitro autoradiography with [125I-Yyr3]-oc- 
treotide the somatostatin receptor status of surgically 
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ated [19]. Ten out of 11 low-grade B-cell lymphomas, 
all of the eight intermediate-grade lymphomas and 
seven out of ten high-grade B-cell lymphomas were so- 
matostatin receptor positive. One T-cell lymphoma was 
positive. Thus overall out of these 30 non-Hodgkin's 
lymphomas, 26 (87%) were somatostatin receptor posi- 
tive. This fact, together with our preliminary aforemen- 
tioned in vivo results, points to [mIn-DTPA-D-Phel]-oc - 
treotide scintigraphy as a very promising localization 
technique for malignant lymphomas. The role of [mIn- 
DTPA-D-Phel]-octreotide scintigraphy in staging Hodg- 
kin's disease and non-Hodgkin's lymphoma is presently 
being investigated in a prospective study. 
Adenocarcinoma of unknown origin. [mIn-DTPA-D- 
Phe~]-octreotide scintigraphy showed multiple lesions in 
nine out of 15 patients with metastases of an adenocar- 
cinoma of unknown origin. Possible primary localiza- 
tions of these turnouts are, for instance, the breast (see 
"breast cancer"), kidney and colon. According to [125I- 
Tyr3]-octreotide autoradiography, 89% and 12% of renal 
cell carcinomas and colon cancers, respectively, express 
somatostatin receptors [13, 58]. 
Granulomatous diseases. In vivo somatostatin receptor 
imaging was positive in all cases of sarcoidosis inves- 
tigated so far (Table 3). Our preliminary data indicate 
that other granulomatous diseases, such as tuberculosis, 
Wegener's granulomatosis, DeQuervain's thyroiditis 
and aspergillosis are also somatostatin receptor positive 
in vivo. It is expected that octreotide scintigraphy may 
contribute to a more precise staging and a better evalu- 
ation of granulomatous diseases. More importantly, it
may be a sensitive indicator of the activity of sarcoido- 
sis and of its response to corticosteroid therapy. 
Autoimmune diseases. With radiolabelled somatostatin 
analogue autoradiography wehave not so far been able 
to find somatostatin receptors in normal thyroid and dif- 
ferentiated thyroid carcinoma (papillary cancer) tissue 
slices [52, 59]. However, a high percentage of malig- 
nant medullary thyroid turnouts (see "Neuroendocrine 
tumours") are somatostatin receptor positive by both au- 
toradiography and [111In-DTPA-D-Phel]-octreotide scin- 
tigraphy [52, 59], and the normal thyroid gland and sev- 
eral differentiated thyroid cancers and their metastases 
have also been found to be somatostatin receptor posi- 
tive with the latter scintigraphic technique. In Graves' 
hyperthyroidism accumulation of radioactivity in the 
thyroid gland is markedly increased [60]. The presence 
of activated lymphocytes in the thyroid gland could ex- 
plain this observation. Indeed, in one thyroid tissue 
sample of Graves' hyperthyroidism investigated with 
[125I-Tyr3]-octreotide autoradiography, a diffuse distribu- 
tion of somatostatin receptors was found, although the 
type of cell which is positive has still to be established 
[J.C. Reubi, unpublished]. In most of the Graves' pa- 
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Fig. 5. a CT of the orbits in a patient with Graves' ophthalmopa- 
thy. b Orbital SPET transversal images (7 mm thickness each, 
the top-down diameter of an orbit is about 3 cm) of the same 
patient, 24 h after injection of [lllIn-DTPA-D-Phel]-octreotide. 
Note the accumulation f radioactivity in the orbits in front of 
the pituitary 
tients treated with methimazole the thyroidal uptake of 
octreotide remains elevated. In hypothyroidism after ra- 
dioiodine treatment for Graves' disease there is no vis- 
ible accumulation of radioactivity in the thyroid. In 
clinically active Graves' ophthahnopathy the orbits 
show accumulation of radioactivity 4 h and 24 h after 
injection of [mIn-DTPA-D-Phel]-octreotide (Fig. 5). 
SPET is required for a proper interpretation f this or- 
bital scintigraphy. The value of [111In-DTPA-D-Phel]-oc- 
treotide scintigraphy in Graves' disease has yet to be 
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established. Possibly this technique could select those 
patients with Graves' ophthalmopathy who might bene- 
fit from treatment with octreotide [61]. 
Rheumatoid arthritis is another autoimmune disease 
with increased accumulation of radioactivity at the sites 
of inflammation. The joints which give rise to the most 
pronounced pain complaints also show the most intense 
uptake of [lllIn-DTPA-D-Phel]-octreotide. Indeed, [125I- 
Tyr3]-octreotide autoradiography of the synovia of an 
affected joint points to the presence of somatostatin re- 
ceptors [M. van Hagen and J.C. Reubi, unpublished]. It 
is of interest that a double-blind, placebo-controlled 
study in patients with rheumatoid arthritis of the knee 
has revealed an immediate reduction of pain with local 
injections of somatostatin [62]. 
Arguments that [1111n-DTPA-D-Phel]-octreotide 
scintigraphy is receptor imaging 
It is indisputable that many of the neuroendocrine tu- 
mours which can be visualized by [mIn-DTPA-D-Phe~]- 
octreotide scintigraphy contain somatostatin receptors. 
Yet many other diseases, which are generally not asso- 
ciated with the classic neuroendocrine characteristics, 
such as granulomas and lymphomas, also show in- 
creased uptake of labelled octreotide. Moreover, precise 
knowledge of which cells or mechanisms are responsi- 
ble for the visualization of autoimmune diseases, spleen 
and thyroid by octreotide scintigraphy is lacking at pre- 
sent. In spite of this, there is ample evidence that oc- 
treotide scintigraphy represents omatostatin receptor 
imaging: 
1. In rats bearing somatostatin receptor-positive tu- 
mours, tumour uptake of [111in_DTPA_D_Phe~]_octreotide 
is prevented by pretreating the animals with high doses 
of unlabelled octreotide [31]. 
2. Using ex vivo [lllln-DTPA-D-Phe~]-octreotide au-
toradiography, i.e. after injection of this radioligand into 
the animal, only the anterior lobe of the rat pituitary, 
which is the only part of this organ with somatostatin 
receptors, showed specific binding of the radioligand 
[31]. 
3. A close correlation exists between the presence of 
somatostatin receptors, demonstrated with in vitro au- 
toradiography and the visualization of tumours and dis- 
eases by in vivo octreotide scintigraphy. This pertains 
not only to an overall comparison between the in vitro 
and in vivo techniques as presented in Tables 1-3, but 
also to the results of both techniques applied to the same 
tumours (see above). 
4. During octreotide treatment, he uptake of [lllIn- 
DTPA-I>Phel]-octreotide in somatostatin receptor-posi- 
tive tumours and the spleen is diminished. This is analo- 
gous to the blocking of receptor binding of iodinated 
octreotide with excess unlabelled octreotide in in vitro 
autoradiography. 
5. Positive scans predict he suppressive effect of oc- 
treotide on hormone secretion from endocrine active tu- 
mours [23, 24]. 
As mentioned under point 1, high-dose octreotide 
pretreatment in rats prevents the in vivo visualization 
of somatostatin receptor-positive tumours. Yet, in our 
experience and that of others, neuroendocrine tumours 
may remain visible during treatment with octreotide, 
though the tumour uptake of [mln-DTPA-i)-Phel]-oc- 
treotide is less (up to 50%) than without octreotide 
treatment. In this respect it should be taken into account 
that many of these tumours contain high numbers of 
somatostatin receptors and that even high doses of oc- 
treotide (1500 btg/day or more subcutaneously) may not 
result in complete occupancy of the somatostatin recep- 
tors. It should also be considered that the expression of 
receptors on a tumour is not a steady state, but a process 
in which recycling of receptors occurs. 
Summarizing, we think that there is sufficient evi- 
dence to conclude that [mIn-DTPA-D-Phe~]-octreotide 
scintigraphy indeed represents somatostatin receptor im- 
aging in vivo. 
Tumours with low-affinity binding 
of octreotide 
The majority of the numerous human turnouts investi- 
gated up to now with [laSI-Tyr3]-octreotide autoradiogra- 
Table 4. Comparison of [H~In-DTPA-D- 
Phel]-octreotide scintigraphy (OC) and 
~23I-MIBG scintigraphy (MIBG) per- 
formed in the same (27) patients a, b 
Tumour type (number) Number of lesions visualized 
OC>MIBG Equal MIBG>OC 
Phaeochromocytoma (8) 2 
Neuroblastoma (5) 0 
Paraganglioma (4) 3 
Carcinoid (1) 0 
Unclassified APUDoma (1) 1 
Medullary thyroid carcinoma (1) 1 








a No uptake in either investigation: carcinoid (1), non-Hodgkin's lymphoma 
haematoma (l), liposarcoma (1), plasma cell granuloma of lung (1) 
b In all patients histological proof of the tumour was obtained 
(2), adrenal 
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phy expressed a somatostatin receptor with a high af- 
finity for octreotide. However, a restricted number of 
somatostatin receptor-containing tumours expressed a
somatostatin receptor subtype with an at least two or- 
ders of magnitude lower affinity for octreotide than SS- 
14. This receptor subtype has been observed in a small 
percentage (<10%) of pituitary adenomas, carcinoids, 
glial tumours, meningiomas and breast cancers and in 
a higher percentage of insulinomas, These insulinomas 
were not visualized with [~231-Tyr3]-octreotide scintigra- 
phy [23]. Approximately 50% of the medullary thyroid 
carcinomas also had this low-affinity somatostatin re- 
ceptor, as did all somatostatin receptor-positive ovarian 
tumours. These findings [13] are in agreement with the 
presence of the cloned somatostatin receptor subtype III 
(see "Somatostatin and somatostatin receptors"). It is 
clear that for scintigraphic and radiotherapeutic pur- 
poses other types of radiolabelled somatostatin ana- 
logues with a high affinity for this receptor subtype will 
have to be developed. 
Comparison of octreotide 
and MIBG scintigraphy 
MIBG scintigraphy is a very sensitive imaging tech- 
nique for phaeochromocytomas and neuroblastomas. It 
is also used to visualize various other tumours that are 
derived from neuroendocrine c lls. In Table 4 a com- 
parison of the results of octreotide scintigraphy and 
MIBG scintigraphy, performed in our hospital in the 
same patients within a period of 2 months, is given. In 
8 of 13 patients with phaeochromocytoma or neuroblas- 
toma, the results of octreotide scintigraphy and MIBG 
scintigraphy were comparable, whereas in two patients 
octreotide scintigraphy demonstrated more tumour sites 
than MIBG scintigraphy and in three patients the re- 
verse was true. Interestingly, octreotide scintigraphy 
was superior to MIBG scintigraphy in five of seven pa- 
tients with other neuroendocrine mmours, four of whom 
had paragangliomas. Examples of the two imaging tech- 
niques in the same patients are given in Figs. 6-8. 
Fig. 6A-D. A comparison between MIBG and octreotide scintig- 
raphy in a patient with multiple paragangliomas. Right (A, B) 
and left (C, D) lateral image of the head and neck. A, C After 
t23I-MIBG; B, D after [mIn-DTPA-D-Pbe~]-octreotide. On the 
right lateral image abnormal uptake of labelled octreotide is seen 
in the parietal region and above the thyroid, as well as the con- 
tralateral temporal paraganglioma (B). With ~3I-MIBG only the 
parietal lesion is faintly visualized (A). On the left lateral image 
increased uptake of labelled octreotide is present in a temporal 
and vagal paraganglioma, while the contralateral parietal metas- 
tasis of the paraganglioma is also seen (D). On the MIBG scin- 
tigram only the parotid and submandibular salivary glands are 
visualized (C). Note that uptake of ~23I-MIBG in the parotid and 
submandibular salivary glands can hamper the recognition of 
paragangliomas 
A comparison between our results with octreotide 
scintigraphy and results of MIBG scintigraphy as re- 
ported in the literature is given in Table 5 [63, 64]. As 
is clear from these data, the two imaging techniques are 
Fig. 7A,B. Three-dimensional re- 
construction from a three-head 
camera of the head of the same 
patient as in Fig. 6. A Left lat- 
eral image; B right lateral image 
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Table 5. Comparison f [Hlln-DTPA-D-Pheq-octreotide scintigra- 
phy (OC) and ~23I-MIBG scintigraphy (MIBG) in different patients 
with comparable tumours. The data on ~23I-MIBG scintigraphy are 
based on the literature [63, 64] 
Tumour type Percentage of 
scans positive (number) 
OC MIBG 
Phaeochromocytoma 86% (14) 88% (>1000) 
Neuroblastoma 89% (9) 91% (841) 
Paraganglioma 100% (33) 52% (25) 
Medullary thyroid carcinoma 71% (28) 35% (178) 
Carcinoid 96% (72) 70% (237) 
Endocrine pancreatic tumour 80% (56) 25% (4) 
Fig. 8. a A comparison between MIBG and octreotide scintigra- 
phy in a patient with a carcinoid of the duodenal papilla. Anterior 
(upper panels) and posterior (lower panels) images of the abdo- 
men. Left panels: After 123I-MIBG; Right panels: after [mIn- 
DTPA-D-Phe~]-octreotide. Th re is pathological uptake of both ra- 
diotracers in two spots in the upper abdomen. Note the visuali- 
zation of the kidneys on the octreotide scintigrams and the higher 
resolution on the posterior images with octreotide scintigraphy, b 
Three-dimensional reconstruction from a three-head camera of the 
upper abdomen of the same patient as in a. Both kidneys are 
visualized and in between them, in purple, is thecarcinoid of the 
duodenal papilla 
about equally sensitive for phaeochromocytomas and 
neuroblastomas. In neuroendocrine tumours other than 
phaeochromocytomas, however, the results of octreotide 
scintigraphy are superior to those obtained with MIBG. 
However, in tumours which show sufficient uptake, an 
advantage of MIBG over octreotide scintigraphy may 
be that positive diagnostic scanning can be followed by 
radiotherapy, whereas therapy with [3-emitting radionu- 
clide-coupled somatostatin analogues is at present still 
not possible. 
Comparison of octreotide 
and monoclonal antibody scintigraphy 
Over the past decade, the use of radiolabelled mono- 
clonal antibodies or fragments thereof or tumour im- 
aging has received much interest. However, despite the 
many promising reports on the potential benefit of ra- 
diolabelled monoclonal antibodies for in vivo tumour 
detection, their widespread application has been ham- 
pered by low tumour to background ratios (because the 
large molecules - Fab 50 kDa, IgG 150 kDa and IgM 
900 kDa - lead to a high background radioactivity) 
(Fig. 2) [65], lack of specificity and human anti-mouse 
antibodies formation. Because of the rapid clearance of 
the small sized [Hlln-DTPA-D-Phel]-octreotide by the 
kidneys (see "Metabolism in man"), much higher tu- 
mour to background ratios can be obtained when la- 
belled octreotide is used instead of labelled monoclonal 
antibodies. Also, there are indeed many convincing ar- 
guments to support he view that octreotide scintigraphy 
is receptor imaging (see above). Lastly, antibody for- 
mation in patients treated with the somatostatin ana- 
logue octreotide is xtremely rare, having until now 
been described in only four cases [66-68] although un- 
dreds of patients with pituitary acromegaly or gastroin- 
testinal neuroendocrine tumours have been treated for 
several years. 
Conclusions 
[111In-DTPA-D-Phe1]-octreotide is a new radiophar- 
maceutical with great potential for the visualization of 
various somatostatin receptor-positive (neuroendocrine) 
tumours, granulomas and (autoimmune) diseases in 
which activated leucocytes play a role. Thus far a lot 
of experience with the first group of patients has been 
obtained by various investigators. The sensitivity of 
[1HIn-DTPA-D-PheX]-octreotide scintigraphy in localiz- 
ing neuroendocrine tumours is high, except in the case 
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of insulinomas. The presence in this tumour of more 
than one subtype of somatostatin receptor with different 
affinities for octreotide necessitates the development of
other somatostatin analogues which, in contrast o oc- 
treotide, also bind with high affinity. Injection of a 
"cocktail" of these analogues, possibly labelled with 
different radionuclides, should increase the sensitivity 
of the technique for this type of tumour. The use of 
[mIn-DTPA-D-Phel]-octreotide whole-body scintigra- 
phy as a first localization technique, e.g. for neuroen- 
docrine tumours, is strongly favoured both by its harm- 
less, non-invasive nature and by the easy interpretation. 
In, for instance, endocrine pancreatic tumours, ultra- 
sonography and CT are usually limited to the pancreas 
and liver region [69], thereby missing possible metas- 
tases, e.g. in the chest, especially in the left supracla- 
vicular region. Inconclusive results with ultrasonogra- 
phy and CT, particularly with tumours less than 2 cm 
in diameter, are usually followed sequentially by inva- 
sive localization methods, e.g. transhepatic selective 
portal venous sampling and selective visceral arteriog- 
raphy. These usual methods may fail to localize the tu- 
mour in 40%-60% of patients [69]. However, intra-op- 
erative ultrasound is probably also a powerful alterna- 
tive to these invasive techniques. 
The value of [mIn-DTPA-D-Phel]-octreotide scinti- 
graphy in other tumours, like breast cancer and malig- 
nant lymphomas and in the above-mentioned diseases, 
has still to be established. The same holds for the use 
of [mIn-DTPA-D-Phe~]-octreotide scintigraphy as a pre- 
dictive tool in discriminating those patients with dis- 
eases not classically known as neuroendocrine who 
might benefit from octreotide treatment. 
Future radiotherapy with radiolabelled chelated so- 
matostatin analogues would be a logical development, 
since it is known that these radioligands bind with high 
affinity to somatostatin receptor positive tumours. The 
rapid decrease in blood radioactivity and the predomi- 
nantly renal clearance are advantageous, although the 
amount of renal accumulation and the relatively long 
renal effective half-life limit the maximally applicable 
radiation dose. Studies are needed to investigate how 
to lower the renal radioactivity, e.g. by co-administra- 
tion of certain drugs and/or amino acids. 
Another application of radiolabelled somatostatin 
analogues is in the use of a hand-held radionuclide 
probe [70] which could help the surgeon as an intra-ab- 
dominal an/or intrathoracic scanner in the search for the 
primary turnout and its metastases and as a guide for 
complete resection of the tumour. Also one could think 
about its external use to try to increase the sensitivity 
of localization of axiilary metastases, e.g. in breast can- 
cer and malignant lymphomas. Of course, for this tech- 
nique a high turnout o background ratio and a relatively 
long effective half-life in the tumour would be essential, 
indicating the need for an appropriate interval between 
injection of the radioligand and use of the probe. 
The basis of somatostatin receptor scintigraphy and 
its reported possibilities, especially in nuclear oncology, 
should encourage many to explore the usefulness of 
other labelled peptides in oncology and immunology. 
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